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Background: Toxins such as LvIA can help elucidate the physiological roles of nAChR subtypes.
Results: Three residues in the 2 subunit were identified as critical to LvIA binding.
Conclusion: The  complementary subunit plays a crucial role in the subtype selectivity of -conotoxin LvIA.
Significance: This study provides new insights into the unique selectivity of LvIA and more broadly into toxin-receptor
interactions.
-Conotoxin LvIA (-CTx LvIA) is a small peptide from the
venomof the carnivorousmarine gastropodConus lividus and is
the most selective inhibitor of 32 nicotinic acetylcholine
receptors (nAChRs) known to date. It can distinguish the 32
nAChR subtype from the 62* (* indicates the other subunit)
and 34 nAChR subtypes. In this study, we performed muta-
tional studies to assess the influence of residues of the 2
subunit versus those of the 4 subunit on the binding of -
CTx LvIA. Although two 2 mutations, 32[F119Q] and
32[T59K], strongly enhanced the affinity of LvIA, the 2
mutation 32[V111I] substantially reduced the binding of
LvIA. Increased activity of LvIA was also observed when the
2-T59L mutant was combined with the 3 subunit. There
were no significant difference in inhibition of 32[T59I],
32[Q34A], and 32[K79A] nAChRs when compared with
wild-type 32 nAChR. -CTx LvIA displayed slower off-rate
kinetics at32[F119Q] and32[T59K] than at the wild-type
receptor, with the latter mutant having the most pronounced
effect. Taken together, these data provide evidence that the 2
subunit contributes to -CTx LvIA binding and selectivity. The
results demonstrate that Val111 is critical and facilitates LvIA
binding; this position has not previously been identified as
important to binding of other 4/7 framework -conotoxins.
Thr59 andPhe119 of the2 subunit appear to interferewith LvIA
binding, and their replacement by the corresponding residues of
the 4 subunit leads to increased affinity.
Nicotinic acetylcholine receptors (nAChRs),3 which com-
prise many different molecular subtypes, are ligand-gated ion
channels that are activated by the endogenous neurotransmit-
ter acetylcholine (ACh) or exogenous nicotine (1, 2). nAChRs
are found in the neuromuscular junction, and in peripheral and
central nervous systems throughout the animal kingdom, and
play important roles in regulating synaptic transmission (3–9).
Neuronal nAChRs are pentameric membrane-bound proteins,
which are made up of  (2–10) and  (2–4) subunits (10).
Pharmacological properties of the heteromeric nAChRs are
influenced by the presence of 2 and/or 4 subunits (11). This
study is part of an ongoing effort to elucidate the physiological
role of each subtype of nAChR and the key binding residue
determinants for selective ligands (12).
-Conotoxins (-CTxs) are a rich source of highly selective
ligands that discriminate among different nAChR subtypes
(13–15). -CTxs contain two conserved disulfide bridges and
are classified into several structural subfamilies according to
the number of residues in the two backbone loops bracketed by
cysteine residues, the largest subfamilies being the 4/7, 4/6, 4/5,
4/4, 4/3, and 3/5 -CTxs. The 4/7 -CTxs are able to discrim-
inate between diverse neuronal - nAChR subunit combina-
tions and stoichiometries (16, 17).
Previous research revealed that some of the 4/7-CTxs, such
as -CTx MII, PnIA, and BuIA, bind to a small conserved cleft
of the 32 nAChR, and the 2 subunit contributes to binding
and selectivity (18, 19). This cleft contains the ligand-accessible
residues 2 Leu121, Val111, Phe119, and Thr59, which act as a
common binding site/pocket for 4/7 -CTxs (18, 19). -CTx
MII from Conus magus is a potent antagonist of 32 and
62* (* indicates the other subunit) nAChRs (20). The -CTx
PnIA is selective on the32 and7 nAChRs (21).-CTxBuIA
fromConus bullatus blocks both 2* (* indicates the other sub-
unit) and4* (* indicates the other subunit) nAChRs, and kinet-
ically distinguishes between themwith long and short off-times
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(22). The 4/7 -CTx LtIA targets a novel microsite and has a
shallow binding site on the 32 nAChR that includes 2 Lys79
outside of the cleft (23). This indicates that different key resi-
dues of the2 subunit are targeted by different-CTxs to block
the 32 nAChR (19, 24).
-CTxLvIA fromConus lividuswas recently characterized and
has high affinity for 32 nAChRs, with an IC50 of 8.7 nM (25).
LvIA is notable for its ability to selectively block 32 versus
6/323 or34 nAChRs. The residues in the2 subunit that
contribute to -CTx LvIA binding to the 32 nAChR remain
unknown.Wethereforeperformedamutational studyof the32
nAChR inwhichwe assessed the influenceof residues that line the
2 subunit on the binding of -CTx LvIA.
EXPERIMENTAL PROCEDURES
Materials—Reagents for peptide synthesis were from GL
Biochem (Shanghai, China). Reversed-phase HPLC analytical
Vydac C18 column (5 m, 4.6 250 mm) and preparative C18
Vydac column (10 m, 22 250 mm) were from Grace Vydac
(Hesperia, CA). Clones of rat3,2, and4 cDNAswere kindly
provided by S. Heinemann (Salk Institute, San Diego, CA).
Peptide Synthesis—A two-step oxidation protocol was used
to synthesize-CTx LvIA as described previously (25). Because
this protocol worked well, we did not attempt a simpler one-
step oxidation approach. In this protocol, linear (see Fig. 1A)
and folded (see Fig. 1B) peptides were purified by HPLC on a
reversed-phase C18 Vydac column. HPLC elution conditions
included a linear gradient of 0–40% solvent B over 40 min.
SolventAwas 0.075% trifluoroacetic acid inH2O. Solvent Bwas
0.05% TFA, 90% acetonitrile in H2O. Absorbance was moni-
tored at 214 nm.
Mutagenesis and Construction of Chimeric 2 Point Muta-
tion Receptors—Point mutants of nAChR 2 subunit cDNA
(see Table 1) were created using PCR and theQuikChange site-
directedmutagenesiskit (Stratagene)accordingtothemanufac-
turer’s instructions. Primers that contained the desired point
mutation as well as at least 15 bases on either side of the muta-
tion were synthesized. The mutagenic primers were extended
and incorporated by PCR. DpnI was then used to digest the
methylated, non-mutated parental cDNA. The point mutated
DNAwas inserted in the pSP65 or pGEMHE vector, which was
transformed into DH5-competent cells. All the PCR muta-
tions were sequenced to confirm incorporation of the desired
mutation (19). The nomenclature for the pointmutants lists the
naturally occurring residue position followed by the change
made, e.g.32[V111I] is a2 subunit with the valine residue at
position 111 position replaced by an isoleucine residue.
cRNA Preparation and Injection into Xenopus laevis Oocytes—
Capped cRNA was synthesized in vitro following linearization
of the plasmid containing template DNA encoding the rat 3,
2, and 4 subunits, as well as the various mutant subunits
using the mMESSAGE mMACHINE in vitro transcription kit
(Applied Biosystems/Ambion, Austin, TX), as described previ-
ously (20). The cRNAwas purified using the Qiagen RNeasy kit
(Qiagen). Their concentration was determined by absorbance
at 260 nm.MatureX. laevis frogs were anesthetized by submer-
sion in 0.1% 3-aminobenzoic acid ethyl ester, and oocytes were
surgically removed. Two collagenase treatments lasting 1 h
were performed at room temperature to remove follicle cells.
RNA transcripts of wild-type 3 subunit with either wild-type
2 ormutant2 subunitweremixed at amolar ratio of 1:1. Fifty
nl of this mixture with10 ng of each cRNA was injected into
each Xenopus oocyte and incubated at 17 °C. Oocytes were
injected within 1 day of harvesting.
Voltage-clamp Recording—Voltage-clamp recordings were
performed 1–4 days after cRNA injection. All recordings were
done at 22 °C room temperature. Briefly, oocytes were volt-
age-clamped at70 mV and exposed to ACh and peptide in a
30-l cylindrical oocyte recording chamber, whichwas gravity-
perfused at a rate of 2 ml/min with ND-96 buffer. The ND-96
buffer consisted of 96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl2,
1.0 mM MgCl2, 1 M atropine, 5 mM HEPES, 0.1 mg/ml bovine
serum albumin, pH 7.1–7.5. The oocyte was subjected once a
minute to a 1-s pulse of 100MACh.Once a stable baselinewas
achieved, either ND-96 alone or ND-96 containing varying
concentrations of the -CTx LvIA wasmanually pre-applied in
a static bath for 5 min prior to the addition of the agonist ACh
pulse.
Data Analysis—Three to five ACh responses were averaged
for the baseline responses of ND-96 after a 5-min incubation
just preceding a test response, which was used to normalize
evoked responses as a percentage of control response. The per-
centage of response of the toxin was divided by the pre-toxin
baseline value to yield a percentage of response. The dose-re-
sponse data were fitted to the equation: % of response  100/
(1  ([toxin]/IC50)nH), where nH is the Hill coefficient, using
GraphPad Prism (GraphPad Software, San Diego, CA). Each
data point of a dose-response curve is the average S.E. from at
least three oocytes. IC50 values were determined by nonlinear
regression analysis using Graph-Pad Prism.
Molecular Modeling—A molecular model of the interaction
between LvIA and the ligand-binding domain of 32 nAChR
was built by homology using the NMR solution structure of
LvIA (ProteinData Bank (PDB) identifier 2mdq) and the crystal
structure of the complex between acetylcholine-binding pro-
tein (AChBP) and conotoxin PnIA variant (PDB identifier 2br8)
as templates, as described previously (25). Themolecularmodel
was refined by a 30-ns explicit water molecular dynamics sim-
ulation carried out with the GROMACS 4.6.5 (26) package and
the ff03 force field (27), using a procedure described previously
(28, 29). All the models of complexes involving 2 subunit
mutants were generated by substituting residue side chains
using Modeler 9v14 (30). This procedure refines the positions
of the substituted side chain atoms as well as of those of the
neighbor residues using a conjugate gradient minimization fol-
lowed by a short molecular dynamics simulation. The molecu-
lar models were refined by a 2-ns explicit water molecular
dynamics simulation, and the simulations of the T59K, V111I,
and F119Q mutants were extended to 10 ns.
RESULTS
Chemical Synthesis of -CTx LvIA—-CTx LvIA linear pep-
tide (Fig. 1A) was successfully synthesized with Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry, in which Cys residues
were orthogonally protected using acid-labile S-trityl and acid-
stable S-acetamidomethyl groups. The acid-labile groups (tri-
2 Subunit Contribution to-CTx LvIA Binding of32 nAChR
9856 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 15•APRIL 10, 2015
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
tyl) were first removed after cleavage of the assembled peptide
chain from the resin. The linear peptide after the initial cleavage
was purified by HPLC with a retention time of 27.7 min (Fig.
1C). Ferricyanide was used to close the first disulfide bridge,
and iodine oxidation was used to subsequently close the second
disulfide bridge. The fully folded peptide of -CTx LvIA with
Cys1–Cys3 and Cys2–Cys4 disulfide bonds (Fig. 1B) was puri-
fied again by HPLC, with a retention time of 27.9 min (Fig. 1D).
The mass of the -CTx LvIA matched that of the amidated
sequence (calculated average mass, 1679.9 Da; observed,
1679.7). This synthesized fully folded peptide was utilized in all
subsequent experiments.
Effect of Mutations of the 2 Subunit on Block by -CTx
LvIA—Previous studies using molecular modeling of related
toxins suggested the nAChR positions that form the ligand-
binding pocket of -conotoxins (23, 31, 32). The residue posi-
tions of the 2 and 4 subunits that were suggested to form the
LvIA-binding pocket in a previous modeling study (25) are
highlighted in Fig. 2. We created point mutations of the 2
subunit where residues in this pocket were replaced with those
found in the homologous position of the 4 subunit. These
mutant receptors were then tested to determine toxin potency
differences (Table 1). Seven nAChR 2 mutants were created,
including Q34A, T59I, T59K, T59L, K79A, V111I, and F119Q.
The concentration-response block by -CTx LvIA on 34
nAChR and wild-type and mutant 32 nAChRs was investi-
gated (Table 1 and Fig. 3). The potency at wild-type 32
FIGURE 1.Reduced-CTx LvIA synthetic intermediate (A) and oxidized, folded-CTx LvIA (B) sequences and correspondingHPLC chromatograms (C
andD).A, sequenceof a synthetic intermediateof-CTx LvIAwithCys2 andCys4 residuesprotectedwith S-acetamidomethyl (Acm), andCys1 andCys3 residues
with free -SH (mercapto) before initial cleavage. The first and third cysteine residueswere initially protectedwith acid-labile groups (trityl),whichwere removed
after cleavage from the resin. B, folded peptide sequences with disulfide connectivity 1–3, 2–4. *, C-terminal carboxamide. C, HPLC chromatograms of the
synthetic intermediate shown in A. D, HPLC chromatograms of oxidized and folded -CTX LvIA. Peptides were analyzed on a reversed-phase analytical Vydac
C18 HPLC using a linear gradient of 0–40% Solvent B over 40 min, where Solvent A  0.075% TFA and Solvent B  0.05% TFA, 90% acetonitrile in H2O.
Absorbance was monitored at 214 nm. Flow rate was 0.75 ml/min. AU, absorbance units.
FIGURE2.Aminoacidsequencealignmentof rat2and4nAChRsubunits,whichhave68.4%sequence identity in their ligand-bindingdomains.The
positions thatweremutated in this study, i.e.positions 34, 59, 79, 111, and119, are indicatedwitharrows.Rectangles indicate the agonist-bindingdomain loops
D, E, and F (3). The subunit positions that were shown to contact LvIA according to a previous molecular modeling study (Luo et al. (25)) are underlined.
TABLE 1
IC50 and Hill slope values for block of nAChRs by -CTx LvIA
Subtypes IC50a Ratiob Hill slope
nM
32 8.67 (6.9–11.0) 1 1.17 (0.88–1.46)
34 148 (103–213) 17 1.14 (0.72–1.55)
32F119Q	 0.58 (0.44–0.76) 0.07 1.12 (0.79–1.44)
32T59K	 0.96 (0.56–1.65) 0.11 0.80 (0.47–1.13)
32T59L	 2.03 (1.52–2.69) 0.23 1.07 (0.77–1.37)
32Q34A	 8.64 (4.80–15.5) 1.0 0.90 (0.22–1.58)
32K79A	 10.8 (6.44–18.0) 1.3 0.86 (0.43–1.30)
32T59I	 15.2 (9.71–23.9) 1.8 1.15 (0.43–1.86)
32V111I	 126 (97.2–163) 15 1.31 (0.66–1.96)
aNumbers in parentheses are 95% confidence intervals.
b IC50/wild-type 32 IC50.
2 Subunit Contribution to-CTx LvIA Binding of32 nAChR
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nAChR was 17-fold greater than that at wild-type 34
nAChR. Among the seven 32 mutants, LvIA had the lowest
activity on 32[V111I], with an IC50 of 126 nM, which is sim-
ilar to the 148 nM IC50 on wild-type 34. Thus, the 2 subunit
mutation V111I reduced the binding of LvIA to 32 nAChR
by 15-fold. There were no significant differences in LvIA
potency on mutants 32 Q34A, K79A, or T59I when com-
pared with activity at wild-type 32 nAChR (Table 1, Fig. 3).
Increased potency of -CTx LvIA was observed at
32[F119Q], 32[T59K], and 32[T59L] nAChRs. LvIA
potently blocked ACh-evoked currents of these nAChRs
with IC50 values of 0.58, 0.96, and 2.03 nM, respectively
(Table 1). The ratio between the IC50 values of wild-type and
mutant 32 nAChRs was 15 and 11 for 32[F119Q] and
32[T59K], respectively. The mutation T59L resulted in only
a small increase (4.3-fold) of LvIA potency. The most LvIA-
sensitive mutant, 32[F119Q], had a potency 2 orders of
magnitude higher than that of the least sensitive mutant,
32[V111I] (Table 1, Fig. 3B).
LvIA is 255-fold less potent at 34 than at 32[F119Q],
and 154-fold less potent at34 than at32[T59K]. Although
introducing the 4 residues Lys and Gln at positions 119 and
59, respectively, increased the potency of LvIA for 32, this
CTx is more potent at wild-type 32 than 34. A synergistic
effect of binding site positions displaying different residues
between the two subtypes might explain why LvIA is more
active at 32 than at 34.
Mutations of the 2 Subunit Affect Recovery Time after Block
by -CTx LvIA—The 32 receptor mutants affected not only
the potency of LvIAbut also its recovery (Table 2, Fig. 4).-CTx
LvIA (10 nM) blocked wild-type 32 nAChRs versus mutant
receptors 32[F119Q], 32[T59K], and 32[V111I] to dif-
ferent degrees (Fig. 4). -CTx LvIA at 10 nM blocked 55%
current of wild-type 32 but produced little or no block of
32[V111I] (Fig. 4,A andB). In contrast, completeblockofACh-
evoked currents was obtained with 10 nM -CTx LvIA onmutant
receptors 32[F119Q] and 32[T59K] (Fig. 4,C andD).
We compared the recovery time (
95% initial current) after
block by 10 M toxin for the wild-type and mutant receptors
(Table 2). Recovery of wild-type 32 nAChR was complete
within 2min after toxin washout. Thus, the t1⁄2 was estimated to
be 30 s, and this time scale is beyond the resolution of the
experimental setup. Similarly the off-rates for 32[T59I],
32[K79A], 32[V111I], and 32[Q34A] were also rapid
(full recovery in 1–3min). The recovery time of wild-type34
nAChR was 20–26 min, which is slower than that of
32[F119Q] (10–12 min), but much faster than 32[T59K].
The three32mutations, T59K, T59L, and F119Q, affected
the off-rates of LvIA significantly, as evidenced by the corre-
sponding receptors having much slower reversible block by
LvIA than wild-type 32 nAChR or mutants T59I, K79A,
V111I, and Q34A. The recovery times of mutants 32[T59L]
and 32[F119Q] were 6–9 and 10–12 min, respectively (Fig.
4C, Table 2), whereas 32[T59K] displayed the slowest recov-
ery time, with less than 3% recovery 20 min after washout
(Table 2). Even at low concentrations of LvIA (10–100 nM),
32[T59K] recovered very slowly from block. At 10 nM LvIA
concentration, 32[T59K] recovered to 28 3.5% current 20
min after washout, and at 100 nM concentration, only 13 2%
current was recovered 20 min after washout (Fig. 4D).
Molecular Modeling—Amolecular model of the interactions
between LvIA and the wild-type 32 nAChR showed that the
2 subunit positions considered for mutations are all poten-
tially in contact with the conotoxin with the exception of posi-
tion 34, as shown in Fig. 5A. LvIA had similar activity at wild-
type and 32Q34A nAChR, in agreement with the absence of
interaction of this position. The wild-type 2 residue Lys79 can
form a surface salt bridge with LvIA Asp11, and this interaction
was found to be stable over a 30-ns molecular dynamics simu-
lation (Fig. 5B). The three other substituted positions, i.e. posi-
tions 59, 111, and 119, are at least partly buried at the interface
with LvIA. The change of activity of LvIA correlated with a
change of buried surface solvent-accessible surface area at
the interface for mutants of positions 59 and 119 (Fig. 5C). The
molecular model did not provide a simple explanation for the
decreased activity of LvIA at the V111Imutant, andwe propose
that this mutation could potentially result in conformational
changes that cannot bemodeled using short molecular dynam-
ics simulations. The other mutated positions, i.e. 59 and 119,
are located in -strands, and the residues chosen for substitu-
FIGURE 3. -CTx LvIA dose-response curves for wild-type and mutant 32 nAChRs. All seven mutant receptors exhibited similar sensitivity for ACh to
wild-type 32 nAChR. Values are mean S.E. from a recording made using 5–9 separate oocytes. Results are summarized in Table 1.
TABLE 2
Recovery time after block by -CTx LvIA
nAChR subtype T95a nAChR subtype T95a
min min
32 2 32T59L	 6–9
32K79A	 1 32F119Q	 10–12
32V111I	 1 34 20–26
32Q34A	 2–3 32T59K	 

20b
32T59I	 2–3
a Time to 95% recovery after toxin washout.
b 3% recovery after 20 min; concentration of -CTx LvIA was 10 M.
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tions are not likely to disrupt this-strand secondary structure.
The 10-ns simulations of complexes incorporating the muta-
tions T59K, V111I, or F1119Q resulted in similar binding
modes with no change of binding site conformation (Fig. 6).
DISCUSSION
Neuronal nAChRs are widely expressed in the CNS and
peripheral nervous system in adults and during development,
but the identification of which subtype is expressed in which
nervous cell is challenging (33–38). LvIA is the first ligand to be
highly specific for32nAChR, and it could potentially be used
in physiological studies of this receptor (25). We sought here to
gain further insights into the binding interactions of LvIA at this
receptor throughmutations of positions that have been shown to
be important for the binding of other-CTxs and ligands (24, 39).
These studies have shown that competitive nicotinic ligands of
FIGURE 4. -CTx LvIA differentially blocks wild-type 32 nAChR (A) and mutant receptors 32[V111I] (B), 32[F119Q] (C), and 32[T59K] (D). The
nAChRs display different reversibility kinetics after block. C indicates control responses to ACh. Oocytes were exposed to 10 nM peptide for 5 min followed by
repetitiveapplicationofACh.-CTxLvIAat10nMblocked55%currentofwild-type32nAChRwith rapid reversibility (A),butdidnotblock32[V111I]nAChR(B).
LvIA at 10 nM blocked100% current ofmutant receptors32[F119Q] nAChRwith slow reversibility (C) and32[T59K] nAChRwith slowest reversibility (D).
FIGURE 5. Molecular modeling of the interaction between LvIA and 32 wild-type and mutant nAChR. A, binding of LvIA (white) into the rat wild-type
32-binding pocket, which comprises the 3 principal subunit (green) and the 2 complementary subunit (blue). The conformation of the side chains of the 2
positions thatweremutatedaredisplayedoverlaidwith thoseof thewild-type receptor. The side chainsof themutants are shown indifferent colors from thoseused
for the wild-type structure. B, distance between the NZ atom of 2 Lys79 and the CG atom of LvIA Asp11 over a 2-ns molecular dynamics simulation. C, correlation
between the differences of buried solvent-accessible surface area betweenwild-type andmutant complexes ( BASA) and the IC50 for the32mutants.
2 Subunit Contribution to-CTx LvIA Binding of32 nAChR
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nAChRs generally bind to both the  subunits and the  subunits
that form a ligand-binding interface (18, 32).
We investigated the influence of seven32nAChRmutants
on the binding of -CTx LvIA. These residues were chosen
based on previous findings with the related -CTx LtIA (23).
Four mutants, 32[F119Q], 32[T59K], 32[T59L] and
32[V111I], had significantly different sensitivity than the
wild-type receptor to -CTx LvIA (Tables 1 and 2; Figs. 3 and
4). The three othermutations, Q34A, K79A and T59I, had little
or no detectable effect on -CTx LvIA activity (Tables 1 and 2;
Figs. 3 and 4). -CTx LvIA at 10 nM blocked55% of the cur-
rent of wild-type 32 with rapid reversibility but blocked

95% of the current of 32[F119Q] and 32[T59K]; the
block of the latter two nAChRs had much slower reversibility
after toxin washout when compared with that observed for the
wild-type 32 nAChR (Fig. 4). The substitution of Phe119 of
the 2 subunit by Gln, which is present in the homologous
position of the 4 subunit (32[F119Q]), resulted in a 15-fold
increase in-CTxLvIApotency. ThemutationT59K caused an
11-fold increase sensitivity for -CTx LvIA, partly due to a
decrease in off-rate (Fig. 4D). A similar finding has been
reported for the 4/4 -CTx BuIA (19). The potency of BuIA at
32[F119Q] and 32[T59K] increased 8- and 20-fold,
respectively, when compared with wild-type 32, with very
slow off-rates. However, BuIA had a faster off-rate but similar
IC50 at32[V111I] versuswild-type32, in contrast to LvIA,
which has a 15-fold decrease in potency at 32[V111I] when
compared with wild-type32 (Table 3) (19). Thus, we suggest
that BuIA and LvIA have overlapping, yet distinct binding
interactions with the receptor. Overall our data suggest that the
three positions on the receptor, 59, 111, and 119, are key to
LvIA binding. Of course, because we examined only a finite
number of mutations, we cannot exclude the possibility that
other positions might also be important.
As far as ligand residues contributing to binding are con-
cerned, the highly conserved Ser-Xaa-Promotif in the first loop
of -CTxs contains a small -helix important for nAChR bind-
ing. -CTx LtIA is atypical because it lacks this Ser-Xaa-Pro
motif and has been suggested to bind a novel microsite on the
32 nAChR (19). -CTx LtIA potentially interacts with 2
Phe119 and 2 Lys79 because the Phe119 and Lys79 mutants dis-
rupted LtIA binding (19), butmutations of these positions were
without effect for activity of -CTxs MII, PnIA, and GID (18).
By contrast, themutation F119Q increased affinity of LvIA, and
the mutation K79A did not affect LvIA activity. The mutation
V111I in the 2 subunit was previously reported to have only a
small effect on the activity of 4/7 -CTxs MII, PnIA, GID (18),
FIGURE 6.Molecular dynamics simulationof LvIA/32 incorporating2
subunit mutations T59K, V111I, or F119Q. A, overlay of the conformation
of the binding sites after 10-ns simulations, with the 3 subunit in green, the
2 subunit in blue, and conotoxin LvIA inwhite. The side chains of LvIA aswell
as the mutated side chains Lys59, Ile111, and Gln119 are in stick representation.
B, backbone root mean square deviation (RMSD) over the 10-ns simulations
from the starting conformation of the 2 subunit binding site. This binding
site is defined here as including the 1 (positions 32–40), 2 (positions
57–63), 5 (positions 109–113), and 6 (positions 116–120) strands.
TABLE 3
IC50 of -conotoxins on nAChR 2 subunit mutants
a Conserved amino acids are shaded in light grey. Conserved cysteine residues are boldface and boxed. Disulfide connectivity of these -conotoxins is Cys1–Cys3 and Cys2–
Cys4. * C-terminal amide.
b Data for LtIA, BuIA, and MII are from previous studies of these toxins tested on the indicated receptors expressed in Xenopus oocytes.
c IC50 in nM.
d Ratio of IC50 of mutant 32 nAChR/IC50 wild-type 32.
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and LtIA (23) (Table 3). By contrast, this mutation decreased
LvIA activity by 15-fold. LvIA displays the conserved Ser-Xaa-
Pro motif in its first loop, suggesting that it adopts a similar
bindingmode tomost 4/7 -CTxs. The sequence in the second
loop of -CTx LvIA is therefore probably a determinant of its
unique selectivity and distinct binding site. Molecular models
indeed suggest that this second loop, especially residues Asn9,
Val10, Asp11, and Pro13, interacts with the 2 subunit. Interest-
ingly, the 4/7 -CTx PeIA also potently blocks 32 nAChRs
and has similar residues in its second loop (31).
The mutant K79A does not show a significant difference in
activity from the wild-type nAChR, but the molecular models
suggest that the Lys79 residue establishes a stable charge inter-
action with LvIA Asp11 (Fig. 5B). It has been proposed that
surface salt bridges can have little contribution to binding affin-
ity because the favorable charge-charge interaction can be
counterbalanced by the negative entropic effect of restraining
the conformation of the side chain (40). This compensation of
enthalpy for entropy components between apo and bound
states is a potential explanation for the innocuous nature of the
K79A substitution. Indeed, the Lys79 side chain is highly
exposed to the solvent and should therefore have considerable
conformational freedom in the absence of the toxin. The side
chain of Lys79 was restrained during the molecular simulations
of the bound toxin, suggesting a significant entropic cost to the
immobilization of the side chain.
Themolecularmodels suggest that substitutions at positions
119 and 59 increase the solvent-accessible surface area buried
at the interface, and this increase correlates with higher affini-
ties of LvIA observed experimentally (Fig. 5C). In particular, the
three mutations, T59I, T59L, and T59K, incrementally intro-
duce longer side chains at position 59, and they result in
increasing inhibitory potency of LvIA. The introduction of a
positively charged Lys at position 59 results in the burial of a
positively charged group, which could be detrimental to bind-
ing, but this residue can potentially interact with the negatively
charged2 subunitGlu61, which is proximally located (Fig. 5A).
The F119Qmutation resulted in better complementarity at the
interface by creating further interactions, especially with LvIA
residues Val10 and Pro13, resulting in the largest buried surface
area among all mutants in this study, in agreement with the
highest inhibitory activity of LvIA among all mutants.
It is interesting to compare the trends in LvIA binding to
32 versus 34 relative to the individual residue substitu-
tions at the three key positions of 59, 111, and 119. In principle,
the decreases in IC50 values associated with the T59K and
F119Q substitutions should more than compensate for the
increased IC50 associated with the V111I substitution. Never-
theless LvIA is 17-fold more potent at 32 than at 34. The
non-additivity of the single point mutant effects can probably
be explained by the spatial organization of these positions
because the side chain at position 119 is sandwiched by those of
positions 111 and 59. The 4 subunit, which displays bulkier
side chains at these positions than the 2 subunit, should pres-
ent a different interface to LvIA than the2 subunit single point
mutants.
In conclusion, we have identified three residues in the
nAChR 2 subunit that are key to the binding interaction of
LvIAwith the 32 nAChR. Furthermore, molecularmodeling
indicates that the sequence of residues in the second loop of
LvIA is particularly important for high affinity for the 32
nAChR. These findings help provide insights into the unique
selectivity profile of this toxin. Understanding interactions
between different -CTxs and 32 nAChR should further
help to elucidate the molecular pharmacology of this subtype.
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